Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT03932903
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
14 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ADAPTS (ADherence Assessments and Personalized Timely Support). — BEHAVIORAL
    ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in AYAs with acute lymphoblastic leukemia and lymphoma. AYA participants will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days. Other features in the app include a medication calendar that syncs with the electronic medication monitor (eCAP) to track daily adherence. A caregiver version of ADAPTS is also available, providing daily surveys (but no randomized mobile messages) and the medication calendar so that dyads can mutually track adherence.

Study Details

This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.

Key Dates

Start date
Jul 31, 2025
Status verified
Dec 2025
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Contextually-tailored Mobile Messages for Adherence
    AYA participants will be micro-randomized to receive contextually-tailored mobile messages designed to promote their oral chemotherapy adherence, with a 60% probability of receiving a contextually-tailored message each day.
  • No Intervention: No messages
    All participants will also be micro-randomized to not receive messages on some days of the intervention (\~40% of the time).

Primary Outcome Measure

Technical Difficulties [ Time Frame: 28-day intervention period ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Robert H. Lurie Comprehensive Cancer Center, Northwestern UniversityChicagoIllinois60611
Alexandra Psihogios, Ph.D.
[email protected]
312-503-3577

Find similar trials in Chicago, IL

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Robert H. Lurie Comprehensive Cancer Center, Northwestern University· Chicago, IL

Related Studies